Literature DB >> 29975413

Pragmatic approaches to address expansion cohort design.

Suzanne E Dahlberg1, Robert J Gray1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29975413      PMCID： PMC6108919          DOI： 10.1002/cncr.31574

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  13 in total

1.  Design considerations for dose-expansion cohorts in phase I trials.

Authors:  Alexia Iasonos; John O'Quigley
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

2.  EGFR Mutations in Non-Small-Cell Lung Cancer: Find, Divide, and Conquer.

Authors:  Daniel Morgensztern; Katerina Politi; Roy S Herbst
Journal:  JAMA Oncol       Date:  2015-05       Impact factor: 31.777

3.  Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.

Authors:  S Percy Ivy; Lillian L Siu; Elizabeth Garrett-Mayer; Larry Rubinstein
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

4.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

5.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Authors:  B J Druker; C L Sawyers; H Kantarjian; D J Resta; S F Reese; J M Ford; R Capdeville; M Talpaz
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

6.  Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience.

Authors:  Suzanne E Dahlberg; Geoffrey I Shapiro; Jeffrey W Clark; Bruce E Johnson
Journal:  J Natl Cancer Inst       Date:  2014-06-24       Impact factor: 13.506

7.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

8.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

9.  Multi-institutional phase I trials of anticancer agents.

Authors:  Afshin Dowlati; Sudhir Manda; Joseph Gibbons; Scot C Remick; Lauren Patrick; Pingfu Fu
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

10.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.